OC
SNDX icon

Oppenheimer & Co’s Syndax Pharmaceuticals SNDX Stock Holding History

Oppenheimer & Co’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-19,809
Closed -$88K – 1387
2018
Q4 		$88K Buy
19,809
+221
+1% +$1.21K ﹤0.01% 1191
2018
Q3 		$158K Buy
19,588
+4,311
+28% +$30.7K ﹤0.01% 1268
2018
Q2 		$107K Sell
15,277
-1,374
-8% -$13.5K ﹤0.01% 1287
2018
Q1 		$237K Buy
16,651
+2,191
+15% +$23.3K 0.01% 1155
2017
Q4 		$127K Sell
14,460
-13,335
-48% -$132K ﹤0.01% 1262
2017
Q3 		$325K Buy
27,795
+1,296
+5% +$15.9K 0.01% 1006
2017
Q2 		$370K Sell
26,499
-95
-0.4% -$1.09K 0.01% 939
2017
Q1 		$365K Buy
+26,594
New +$276K 0.01% 922

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Oppenheimer & Co's SNDX Position: Q1 2019 in Review

Oppenheimer & Co sold out of Syndax Pharmaceuticals (SNDX) in Q1 2019, closing a stake of 19,809 shares — an estimated $88K sold.

Oppenheimer & Co first reported a position in SNDX in Q1 2017 and held it in 8 quarters. The position peaked at $370K in Q2 2017. 69 funds tracked by Wall St. Rank hold SNDX as of Q1 2019.

  • Oppenheimer & Co reported no remaining Syndax Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Oppenheimer & Co sold 19,809 Syndax Pharmaceuticals shares in Q1 2019, an estimated $88K.
  • Oppenheimer & Co first reported a position in Syndax Pharmaceuticals in Q1 2017 and held it in 8 quarters.
  • Oppenheimer & Co's Syndax Pharmaceuticals position peaked at $370K in Q2 2017.
  • 69 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2019.

Based on Oppenheimer & Co's 13F filing for Q1 2019, filed 24 Apr 2019.